These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 32768872)

  • 1. Fibrolamellar carcinoma: Challenging the challenge.
    Lamarca A; Frizziero M; Fulton A; McNamara MG; Filobbos R; Hubner RA; Wardell S; Valle JW
    Eur J Cancer; 2020 Sep; 137():144-147. PubMed ID: 32768872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful Liver Transplantation of Recurrent Fibrolamellar Carcinoma following Clinical and Pathologic Complete Response to Triple Immunochemotherapy: A Case Report.
    Kang S; Magliocca J; Sellers M; Roccaro G; Zheng W; Pectasides M; Draper A; Guadagno J; El-Rayes B; Akce M
    Oncol Res Treat; 2022; 45(7-8):430-437. PubMed ID: 35537414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatic arterial infusion chemotherapy in combination with pegylated interferon-α-2b for advanced hepatocellular carcinoma.
    Okita K; Yamasaki T; Hamabe S; Saeki I; Harima Y; Terai S; Sakaida I
    Hepatogastroenterology; 2012; 59(114):533-7. PubMed ID: 22353519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical pilot study of intrahepatic arterial chemotherapy with methotrexate, 5-fluorouracil, cisplatin and subcutaneous interferon-alpha-2b for patients with locally advanced hepatocellular carcinoma.
    Urabe T; Kaneko S; Matsushita E; Unoura M; Kobayashi K
    Oncology; 1998; 55(1):39-47. PubMed ID: 9428374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma.
    Patt YZ; Hassan MM; Lozano RD; Brown TD; Vauthey JN; Curley SA; Ellis LM
    J Clin Oncol; 2003 Feb; 21(3):421-7. PubMed ID: 12560429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Similar effects of recombinant interferon-alpha-2b and natural interferon-alpha when combined with intra-arterial 5-fluorouracil for the treatment of advanced hepatocellular carcinoma.
    Uka K; Aikata H; Takaki S; Miki D; Jeong SC; Hiramatsu A; Kodama H; Shirakawa H; Kawakami Y; Takahashi S; Toyota N; Ito K; Chayama K
    Liver Int; 2007 Nov; 27(9):1209-16. PubMed ID: 17919232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized, phase II study comparing interferon combined with hepatic arterial infusion of fluorouracil plus cisplatin and fluorouracil alone in patients with advanced hepatocellular carcinoma.
    Yamashita T; Arai K; Sunagozaka H; Ueda T; Terashima T; Yamashita T; Mizukoshi E; Sakai A; Nakamoto Y; Honda M; Kaneko S
    Oncology; 2011; 81(5-6):281-90. PubMed ID: 22133996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic efficacy of multimodal combination therapy using transcatheter arterial infusion of epirubicin and cisplatin, systemic infusion of 5-fluorouracil, and additional percutaneous ethanol injection for unresectable hepatocellular carcinoma.
    Jang JW; Park YM; Bae SH; Choi JY; Yoon SK; Chang UI; Nam SW; Kim BS
    Cancer Chemother Pharmacol; 2004 Nov; 54(5):415-20. PubMed ID: 15235823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The progress of hepatic arterial infusion chemotherapy for hepatocellular carcinoma].
    Noda T; Nagano H; Wada H; Marubashi S; Miyamoto A; Takeda Y; Umeshita K; Dono K; Ohsuga K; Kim T; Tomoda K; Nakamura H; Monden M
    Gan To Kagaku Ryoho; 2006 Sep; 33(9):1221-5. PubMed ID: 16969014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibrolamellar hepatocellular carcinoma in an infant and literature review.
    Cruz O; Laguna A; Vancells M; Krauel L; Medina M; Mora J
    J Pediatr Hematol Oncol; 2008 Dec; 30(12):968-71. PubMed ID: 19131794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A case of fibrolamellar cancer with a palliative response and minor radiographic regression with erlotinib and bevacizumab combination therapy.
    Fakih M
    Am J Ther; 2014; 21(6):e207-10. PubMed ID: 23676344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Durable clinical and pathologic response of hepatocellular carcinoma to systemic and hepatic arterial administration of platinol, recombinant interferon alpha 2B, doxorubicin, and 5-fluorouracil: a communication.
    Patt YZ; Hoque A; Roh M; Ellis L; Lozano R; Carrasco CH; Charnsangavej C; Cleary K
    Am J Clin Oncol; 1999 Apr; 22(2):209-13. PubMed ID: 10199464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Arterial infusion of 5-fluorouracil combined with subcutaneous injection of pegylated interferon alpha-2b in treating unresectable hepatocellular carcinoma with portal vein tumor thrombus.
    Wu J; Huang WJ; Wang HY; Wang YF; Peng BG; Zhou Q
    Med Oncol; 2015 Mar; 32(3):65. PubMed ID: 25691293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A case of recurrent hepatocellular carcinoma successfully treated with a combination therapy of interferon-alpha and intravenous continuous infusion of 5-fluorouracil].
    Katsuramaki T; Furuhata T; Kimura Y; Yamaguchi K; Ohmura T; Hata F; Mukaiya M; Hirata K
    Gan To Kagaku Ryoho; 2002 Oct; 29(10):1801-4. PubMed ID: 12402433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatic arterial infusion of 5-fluorouracil in combination with subcutaneous interferon-alpha for advanced hepatocellular carcinoma.
    Kuroda M; Kobayashi Y; Urawa N; Yamamoto M; Mifuji R; Araki J; Tanaka H; Horiike S; Itani T; Furjita N; Konishi M; Iwasa M; Kaito M; Adachi Y
    Hepatogastroenterology; 2007 Mar; 54(74):518-21. PubMed ID: 17523311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatic intra-arterial interferon alpha 2b-based immunotherapy combined with 5-fluorouracil (5-FU)-based systemic chemotherapy for patients with hepatocellular carcinoma (HCC) not responsive and/or not eligible for conventional treatments: a pilot study.
    Vitale FV; Romeo P; Vasta F; Panebianco V; Calì S; Rotondo S; Ferraù F; La Greca M
    Anticancer Res; 2007; 27(6B):4077-81. PubMed ID: 18225574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic efficacy of combination therapy with intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma with portal venous invasion.
    Kasai K; Ushio A; Kasai Y; Sawara K; Miyamoto Y; Oikawa K; Kuroda H; Takikawa Y; Suzuki K
    Cancer; 2012 Jul; 118(13):3302-10. PubMed ID: 22072099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interstitial pneumonia induced by combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma.
    Yamamoto S; Tomita Y; Hoshida Y; Iizuka N; Marubashi S; Miyamoto A; Nagano H; Dono K; Umeshita K; Nakamori S; Sakon M; Aozasa K; Monden M
    J Gastroenterol; 2004 Aug; 39(8):793-7. PubMed ID: 15338375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatic arterial infusion chemotherapy using high-dose 5-fluorouracil and cisplatin with or without interferon-alpha for the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis.
    Eun JR; Lee HJ; Moon HJ; Kim TN; Kim JW; Chang JC
    Scand J Gastroenterol; 2009; 44(12):1477-86. PubMed ID: 19958061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effective treatment for advanced hepatocellular carcinoma with portal venous invasion using a combination therapy of intra-arterial 5-fluorouracil and subcutaneous pegylated-interferon-alpha-2b.
    Mawatari H; Kirikoshi H; Yoneda M; Higurashi T; Fujita K; Saito S; Inamori M; Takahashi H; Abe Y; Kubota K; Nakajima A
    Hepatogastroenterology; 2008; 55(86-87):1776-7. PubMed ID: 19102391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.